Head and neck cancers are a heterogeneous collection of malignancies of the upper
aerodigestive tract, salivary glands and thyroid. In this Review, we primarily focus on the …

Three randomized phase III trials have now conclusively proven that exposure to a PD-1
inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such …

Head and neck squamous cell carcinomas (HNSCCs) are highly aggressive, multi-factorial
tumors in the upper aerodigestive tract affecting more than half a million patients worldwide …

The immune system plays a key role in the development, establishment, and progression of
head and neck squamous cell carcinoma (HNSCC). A greater understanding of the …

There is increasing evidence supporting a role for B cells in tumor immunology.
Paraneoplastic syndromes occurring before a cancer diagnosis have pointed to the potential …

Simple Summary Even with recent advances, there are urgent needs for novel therapies to
improve overall survival and decrease toxicities in the management of head and neck …

With the advent of combined immunotherapies, personalized dendritic cell (DC)-based
vaccination could integrate the current standard of care for the treatment of a large variety of …

Head and neck squamous cell carcinoma (HNSCC) carries a poor prognosis, with low
survival rates for advanced stage tumors and minimal improvement in survival trends …

TP53, which encodes the tumour-suppressor protein p53, is the most frequently mutated
gene across all cancer types. The presence of mutant p53 predisposes to cancer …

Carcinogenesis is a multistep process attributable to both gain‐of‐function mutations in
oncogenes and loss‐of‐function mutations in tumor suppressor genes. Currently, most …